[CAL-101,a novel agent of targeted therapy in hematological malignancies].

Abstract	CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.
Authors	Chan-Juan Li, Qing Zhang, Yi-Zhuo Zhang
Journal	Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 22 Issue 2 Pg. 530-3 (Apr 2014) ISSN: 1009-2137 [Print] China
PMID	24763037 (Publication Type: Journal Article, Review)
Chemical References	Phosphoinositide-3 Kinase Inhibitors Purines Quinazolinones idelalisib
Topics	Animals Hematologic Neoplasms (drug therapy) Humans Phosphoinositide-3 Kinase Inhibitors Purines (pharmacology, therapeutic use) Quinazolinones (pharmacology, therapeutic use) Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!